Michael Mager, Precision Neuroscience | theCUBE + NYSE Wired: MedTech Unplugged

In this episode of MedTech Unplugged, Michael Mager, co-founder and CEO of Precision Neuroscience, discusses the advancements in brain-computer interfaces (BCIs) with a focus on their innovative Layer-7 implant technology. This groundbreaking development promises to connect human thoughts with artificial intelligence (AI), allowing individuals, particularly those with paralysis, to control devices using their minds. The conversation unfolds at theCUBE's New York Stock Exchange studio, exploring the challenges, potential, and the revolutionary impact of BCIs on human health and digital interaction. Mager elaborates on the importance of non-invasive, high-resolution systems, the company's path toward FDA clearance, and the significant role AI plays in processing neural data. Precision Neuroscience aims to redefine safety and efficacy standards in medical technology, a sentiment echoed by experts in the industry.

• Overview of Layer-7 implant technology and its applications.
• Transformative benefits of brain-computer interfaces for individuals with paralysis.
• Importance of maintaining non-invasive design with high-resolution capabilities.
• Challenges faced in obtaining FDA clearance and the significance of their recent achievement.
• The role of AI in processing and interpreting complex neural data.
• Current status of patient implants and ongoing studies at leading medical institutions.
• Insights into the company's business model, funding, and future growth plans.
• Discussion of ethical considerations and the commitment to safety within the BCI industry.